Breviscapine Ameliorates Fear Extinction and Anxiety in BALB/cJ Mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective In this research, the influence of breviscapine on anxiety, fear elimination, and aggression and the potential mechanism was investigated.Methods Anxiety and locomotion were analyzed by elevated plus maze and open field test in mice. Bussey-Saksida Mouse Touch Screen Chambers were used to perform fear conditioning. Territorial aggression was assessed by resident intruder test. Protein levels were evaluated by Western blot. Breviscapine improved fear-extinction learning in BALB/cJ mice.Results Breviscapine at 20–100 mg/kg increased center cross number, total distance traveled, and velocity in a dose-dependent manner. On the other hand, breviscapine at 20–100 mg/kg decreased the immobility time in open field test. In addition, breviscapine at 20–100 mg/kg increased the ratio of time on the open arm, time on the distal parts of the open arm, and total distance traveled in elevated plus maze. Breviscapine at 100 mg/kg increased the average attack latency and decreased the number of attacks over the last 3 days of resident intruder test. In hippocampus, protein levels of postsynaptic density protein-95 and synaptophysin were elevated by breviscapine at these three doses.Conclusion The administration of breviscapine alleviates fear extinction, anxiety, and aggression, while increases locomotor in a dose-dependent manner, which might be associated with its influence on synaptic function.
Abstract
Objective In this research, the influence of breviscapine on anxiety, fear elimination, and aggression and the potential mechanism was investigated.Methods Anxiety and locomotion were analyzed by elevated plus maze and open field test in mice. Bussey-Saksida Mouse Touch Screen Chambers were used to perform fear conditioning. Territorial aggression was assessed by resident intruder test. Protein levels were evaluated by Western blot. Breviscapine improved fear-extinction learning in BALB/cJ mice.Results Breviscapine at 20–100 mg/kg increased center cross number, total distance traveled, and velocity in a dose-dependent manner. On the other hand, breviscapine at 20–100 mg/kg decreased the immobility time in open field test. In addition, breviscapine at 20–100 mg/kg increased the ratio of time on the open arm, time on the distal parts of the open arm, and total distance traveled in elevated plus maze. Breviscapine at 100 mg/kg increased the average attack latency and decreased the number of attacks over the last 3 days of resident intruder test. In hippocampus, protein levels of postsynaptic density protein-95 and synaptophysin were elevated by breviscapine at these three doses.Conclusion The administration of breviscapine alleviates fear extinction, anxiety, and aggression, while increases locomotor in a dose-dependent manner, which might be associated with its influence on synaptic function.
참고문헌 (25)
- Gao J, "Therapeutic effects of breviscapine in cardiovascular diseases : a review", Front Pharmacol, 8, pp.289~ (2017)
- Wen L, "Breviscapine : a review on its phytochemistry, pharmacokinetics and therapeutic effects", Am J Chin Med, 49, pp.1369~1397 (2021)
- Noordermeer SD, "A systematic review and meta-analysis of neuroimaging in oppositional defiant disorder(ODD)and conduct disorder(CD)taking attention-deficit hyperactivity disorder(ADHD)into account", Neuropsychol Rev, 26, pp.44~72 (2016)
- Jager A, "Methylphenidate dose-dependently affects aggression and improves fear extinction and anxiety in BALB", cJ mice, 2019, pp.10, 768~
- Pellow J, "Complementary and alternative medical therapies for children with attention-deficit", hyperactivity disorder(ADHD), 2011, pp.16, 323~337
- Zablotsky B, "Prevalence and trends of developmental disabilities among children in the United States : 2009-2017", Pediatrics, 144, pp.e20190811~ (2019)
- Pang X, "Attention deficit hyperactivity disorder(ADHD)among elementary students in rural China : prevalence, correlates, and consequences", J Affect Disord, 293, pp.484~491 (2021)
- Michielsen M, "Prevalence of attention-deficit hyperactivity disorder in older adults in the Netherlands", Br J Psychiatry, 201, pp.298~305 (2012)
- Biederman J, "Predictors of persistence and remission of ADHD into adolescence : results from a four-year prospective follow-up study", J Am Acad Child Adolesc Psychiatry, 35, pp.343~351 (1996)
- Wenthur CJ, "Classics in chemical neuroscience : methylphenidate", ACS Chem Neurosci, 7, pp.1030~1040 (2016)
- Lyu J, "Clinical evidence and GRADE assessment for breviscapine injection(DengZhanHuaSu)in patients with acute cerebral infarction", J Ethnopharmacol, 262, pp.113137~ (2020)
- Li Z, "Breviscapine exerts neuroprotective effects through multiple mechanisms in APP", PS1 transgenic mice, 2020, pp.468, 1~11
- Li Y, "Breviscapine alleviates cognitive impairments induced by transient cerebral ischemia", reperfusion through its anti-inflammatory and anti-oxidant properties in a rat model, 2020, pp.11, 4489~4498
- Xia H, "Effects of breviscapine on amyloid beta 1-42 induced Alzheimer’s disease mice : a HPLCQTOF-MS based plasma metabonomics study", J Chromatogr B Analyt Technol Biomed Life Sci, 1057, pp.92~100 (2017)
- Purper-Ouakil D, "Emotional dysfunctions in attention deficit hyperactivity disorder", Arch Pediatr, 18, pp.679~685 (2011)
- Schatz DB, "ADHD with comorbid anxiety : a review of the current literature", J Atten Disord, 10, pp.141~149 (2006)
- Spencer AE, "Abnormal fear circuitry in attention deficit hyperactivity disorder : a controlled magnetic resonance imaging study", Psychiatry Res Neuroimaging, 262, pp.55~62 (2017)
- Kida S, "Reconsolidation", destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD, 2019, pp.236, 49~57
- Patel BD, "Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression : a review", Psychiatr Q, 84, pp.407~415 (2013)
- An XL, "Strain and sex differences in anxiety-like and social behaviors in C57BL", 6J and BALB, Exp Anim, pp.2011, 60[DOI]
- Zeng YQ, "Scutellarin mitigates Aβ-induced neurotoxicity and improves behavior impairments in AD mice", Molecules, 23, pp.869~ (2018)
- Liu L, "Association between SYP with attention-deficit", hyperactivity disorder in Chinese Han subjects : differences among subtypes and genders, 2013, pp.210, 308~314
- Ugalde-Triviño L, "PSD-95 : an effective target for stroke therapy using neuroprotective peptides", Int J Mol Sci, 22, pp.12585~ (2021)
- Prybylowski K, "The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2", Neuron, 47, pp.845~857 (2005)
- Qin L, "The ADHD-linked human dopamine D4 receptor variant D4. 7 induces over-suppression of NMDA receptor function in prefrontal cortex", Neurobiol Dis, 95, pp.194~203 (2016)